Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
Cancer Cell. 2013 May 13;23(5):563-5. doi: 10.1016/j.ccr.2013.04.028.
In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B cell activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible process is specifically targetable and hence presents high translational value for lymphoma therapy.
在本期《癌细胞》杂志中，贝格林及其同事强调了 EZH2 作为 B 细胞激活的必需调节剂，并报告了生发中心衍生肿瘤对 EZH2 活性的依赖性。这个可逆转的过程具有明确的靶向性，因此对淋巴瘤治疗具有很高的转化价值。
